Heart Failure Pipeline Insight
DelveInsight’s, “Heart Failure - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Heart Failure Understanding
Heart Failure: Overview
Heart Failure, also known as congestive heart failure refers to the condition when heart is not able to pump adequate blood to the body. In the absence of sufficient blood flow, all the major body functions are disrupted. Certain conditions, such as narrowed arteries in the heart (coronary artery disease) or high blood pressure, gradually leave the heart too weak or stiff to fill and pump efficiently. Heart failure can be diagnosed based on the medical and family history, a physical exam, and test results. Treating heart failure depends on the severity of the condition. Diagnostic tests include: electrocardiogram, chest X-Ray, echocardiography etc. Treatments usually include heart-healthy lifestyle changes, medicines, and ongoing care.
"Heart Failure- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart failure treatment guidelines. The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart failure.
Heart Failure Emerging Drugs Chapters
This segment of the Heart Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart Failure Emerging Drugs
Pecavaptan (BAY-1753011): Bayer
BAY 1753011, a novel, dual-acting vasopressin receptor antagonist. The company is recruiting for a multicenter, randomized, double-blind, active and placebo-controlled study (phase 2 of clinical trials) of BAY1753011 in patients who have congestive heart failure.
Omecamtiv Mecarbil: Amgen
Omecamtiv mecarbil, previously referred to as CK-1827452, is a cardiac-specific myosin activator. Experimental studies on rats and dogs, proved the efficacy and mechanism of action of omecamtiv mecarbil. Current clinical studies on humans have shown there is a direct linear relationship between dose and systolic ejection time
Further product details are provided in the report……..
Heart Failure: Therapeutic Assessment
This segment of the report provides insights about the different Heart Failure drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Heart Failure
There are approx. 10+ key companies which are developing the therapies for Heart Failure. The companies which have their Heart Failure drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Bayer and others.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Gene Therapy
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Heart Failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure drugs.
Heart Failure Report Insights
- Heart Failure Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Heart Failure Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Heart Failure drugs?
- How many Heart Failure drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart Failure therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heart Failure and their status?
- What are the key designations that have been granted to the emerging drugs?